(CTABF) –
-
Canntab Announces Corporate Update
-
CANNTAB ANNOUNCES ITS ENTRANCE INTO THE NOVA SCOTIA CANNABIS MARKET
-
CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO
-
Canntab Corporate Update
-
CANNTAB ANNOUNCES CHANGE OF AUDITOR
-
Canntab Engages Hamish Sutherland as Strategic Advisor
-
CANNTAB SIGNS AFFILIATE AGRREMENT WITH ONPHARM-UNITED
-
CANNTAB SIGNS HISTORIC AGREEMENT WITH FIRST NATIONS GROWERS GP INC. TO ADDRESS THE OPIATE AND ILLICIT DRUG CRISIS AFFECTING INDIGENOUS PEOPLES THROUGHOUT CANADA
-
CANNTAB ANNOUNCES CLOSING OF CONVERTIBLE DEBENTURE PRIVATE PLACEMENT, WARRANT EXPIRY EXTENSION AND CORPORATE UPDATE
-
CANNTAB OFFICIALLY LAUNCHES ITS ONLINE E-COMMERCE PLATFORM
-
Levitee Labs Partners with Canntab Therapeutics to Provide Alternatives to Opioids
-
CANNTAB DELIVERS 1st SHIPMENT TO THE ONTARIO CANNABIS STORE AND 2nd SHIPMENT TO AUSTRALIA
-
CANNTAB ENTERS INTO STRATEGIC PARTNERSHIP TO PROVIDE ALTERNATIVES TO OPIATES THROUGH LEVITEE CLINICS
-
Canntab Receives Medical Sales Licence from Health Canada
-
Canntab Reaches Agreement with Innovative Bioinformatics Company, 36eight Technologies Inc.
-
Canntab Announces the Early Exercise of $1,259,250 Warrants
-
Canntab Receives Export License Approval from Health Canada
-
Canntab Granted 3rd Patent and Receives $400K Purchase Order in Australia
-
Canntab Granted 2nd Patent For Immediate Release Cannabidiol Formulation Tablets
-
Canntab Begins Delivery of Tablets to MediPharm
-
Canntab to Launch in Australia and Participate in Australia's Largest Cannabis Research Study
-
Canntab Granted 1st US Patent Covering Multi-Layer (Bi-Layer) Tablets
-
Canntab announces planned purchases of cannabis processing equipment and leasehold improvements
-
Canntab Appoints Larry Latowsky as CEO
-
Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement
-
Canntab Appoints Joshi Laxminarayan as Chief Scientific Officer
-
Canntab to Present at the Canaccord Genuity 2020 Virtual Cannabis Conference
-
Canntab Closes Final Tranche of Private Placement for Aggregate Proceeds of $3.7m
-
Canntab Announces Replacement of Advisor Warrants and Intention to Appoint Larry Latowsky as Director and Executive Chairman of the Board
-
Canntab Receives Health Canada Licence and Closes $3.08M Offering
-
Canntab Awarded Health Canada Cannabis Research Licence
-
Canntab Announces Non-Brokered Private Placement
-
Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status
-
Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-derived CBD Oil and the Distribution of Canntab's Hard Pill Formulations
-
Canntab Achieves Key Milestone: Canntab Enters Into Supply & Distribution Agreements With Exactus for the Purchase of Hemp-Derived CBD Oil and the Distribution of Canntab's Hard Pill Formulat
-
Exactus, Inc. Enters into Supply & Distribution Agreement with Canntab Therapeutics to Produce Immediate and Extended Release Tablets
-
Canntab to utilize the advanced BOSS extraction system from Word Class Extractions to further its own extraction capabilities
-
Canntab Receives Initial Indication of Patentability for Immediate Release Cannabidiol Formulation
-
Canntab provides corporate update
-
Canntab Signs Term Sheet with Heritage for Processing Hemp for Sale of CBD Filled Gelcaps
-
Canntab signs term sheet with Heritage for processing hemp for sale of CBD filled gelcaps
-
Canntab Receives Cultivation Licence for Industrial Hemp
-
Canntab Therapeutics Now Trading on the OTCQX Best Market
-
OTC Markets Group Welcomes Canntab Therapeutics Ltd to OTCQX
-
Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada
-
Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal
-
Canntab Provides Corporate Update
Back to CTABF Stock Lookup
